{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T12:58:37Z","timestamp":1780145917174,"version":"3.54.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013161","name":"Swiss Life Stiftung f\u00fcr Chancenreichtum und Zukunft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013161","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.cgh.2022.08.026","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T14:12:56Z","timestamp":1662387176000},"page":"2195-2196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Carvedilol as Best \u03b2-Blocker for Secondary Prophylaxis of Variceal Bleeding: Are We There, or Not Yet?"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3414-0055","authenticated-orcid":false,"given":"Jaume","family":"Bosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2022.08.026_bib1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII: renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.08.026_bib2","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1136\/gutjnl-2012-304182","article-title":"Carvedilol: the beta-blocker of choice for portal hypertension?","volume":"62","author":"Bosch","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2022.08.026_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis","author":"Villanueva","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.08.026_bib4","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/hep.23689","article-title":"Carvedilol for portal hypertension in patients with cirrhosis","volume":"51","author":"Bosch","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.08.026_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/apt.12634","article-title":"Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis","volume":"39","author":"Sinagra","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.08.026_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.510300124","article-title":"Carvedilol, a new nonselective beta-blocker with intrinsic anti-Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis","volume":"30","author":"Banares","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.08.026_bib7","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/hep.1840360612","article-title":"Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis","volume":"36","author":"Banares","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.08.026_bib8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2036.2002.01190.x","article-title":"Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension","volume":"16","author":"Tripathi","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.08.026_bib9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/apt.16189","article-title":"Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study","volume":"53","author":"McDowell","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.08.026_bib10","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2022.08.026_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/hep.23045","article-title":"Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed","volume":"50","author":"Tripathi","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.08.026_bib12","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.cgh.2022.06.007","article-title":"Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis","volume":"21","author":"Jachs","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.08.026_bib13","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(95)91740-3","article-title":"Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis","volume":"346","author":"Feu","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2022.08.026_bib14","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2006.09.013","article-title":"Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review","volume":"131","author":"D'Amico","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.08.026_bib15","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/jhep.2003.50133","article-title":"Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis","volume":"37","author":"Abraldes","year":"2003","journal-title":"Hepatology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522008096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522008096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:44:16Z","timestamp":1761543856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356522008096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1542356522008096"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2022.08.026","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carvedilol as Best \u03b2-Blocker for Secondary Prophylaxis of Variceal Bleeding: Are We There, or Not Yet?","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2022.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2022.06.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the AGA Institute","name":"copyright","label":"Copyright"}]}}